Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors

Xiaorong Dong, Xingya Li, Jianhua Chen, Shenglin Ma, Deguang Mu, Jie Hu, Shun LüJTO 2022 · DOI

Abstract

The selective c-MET inhibitor HS-10241 was well tolerated and had clinical activity in advanced NSCLC, especially in patients with positive MET. Furthermore, this study expounds on the therapeutic potential of HS-10241 in patients with cancer.
BibTeX
@inproceedings{dong2022phase,
  author = {Xiaorong Dong and Xingya Li and Jianhua Chen and Shenglin Ma and Deguang Mu and Jie Hu and Shun Lü},
  title = {{Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors}},
  booktitle = {JTO},
  year = {2022},
  doi = {10.1016/j.jtocrr.2022.100449},
}

Loading related content...

Figure